https://www.selleckchem.com/products/S31-201.html
7yr vs. 57.0yr, P0.0001), with a lower proportion of ASCVD risk factors. Interestingly, patients identified through cascade screening under milder lipid-lowering therapies were at reduced risk for MACE (hazard ratio [HR]=0.67; 95%CI=0.44 to 0.90; P=0.0044) when compared with the probands, even after adjusting for those known risk factors, including age, and prior ASCVD. The identification of patients with FH via cascade screening appeared to result in better prognosis. The identification of patients with FH via cascade screening app
Like
Comment
Share
